Verkazia (cyclosporine) is an eye medication used to ease swelling and itchiness on the surface of the eye from a rare allergic condition called vernal keratoconjunctivitis (VKC). It's FDA approved for use in both adults and children ages 4 years and up. The dose is to place one drop in the affected eye(s) 4 times a day. The most common side effects include temporary eye pain after applying the medication.
Vernal keratoconjunctivitis (VKC), an allergic eye condition
Verkazia (cyclosporine) is a calcineurin inhibitor. Calcineurin is a protein in your body that raises inflammation, including your eyes.
Although it's not clear how Verkazia (cyclosporine) works in the eyes, it's thought that the medication lowers eye inflammation, which helps to relieve symptoms of vernal keratoconjunctivitis (VKC).
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
Can be used with other lubricating eye drops, such as artificial tears
Safe to use in children 4 years of age and older
Able to stop use after VKC symptoms go away
Needs to be used 4 times a day
Can cause some eye pain after application
Can't be used with contact lenses
Always wash your hands with soap and water before using Verkazia (cyclosporine). The medication should only be applied to your eyes
If you miss a dose of Verkazia (cyclosporine), just continue with your regular dosing schedule and take the next dose as planned.
If you need to use another eye drop in the same eye, wait at least 10 minutes after using Verkazia (cyclosporine). This gives enough time for both eye medications to absorb properly into your eye(s).
If you need to use another eye ointment or gel in the same eye, use Verkazia (cyclosporine) first and wait at least 10 minutes before applying the other product. This is because thicker eye ointments or gel can prevent Verkazia (cyclosporine) from being fully absorbed.
Make sure to take your contact lenses out before using Verkazia (cyclosporine). Wait at least 15 minutes before putting your lenses back in.
Don't let the tip of the Verkazia (cyclosporine) vial touch the eye or other surfaces. Doing so can contaminate the medication with bacteria.
Gently shake the Verkazia (cyclosporine) vial before using it. This will make sure the eye emulsion is properly mixed and ready for application.
Keep the single-use vials of Verkazia (cyclosporine) in the original package and don't open them until you're ready to use the medication. This helps to protect the vials from light and heat.
After you've used a drop of Verkazia (cyclosporine) in your affected eye(s), throw the vial away. Don't save the leftover medication. Since single-use vials don't contain preservatives to prevent bacteria from growing, using leftover medication can raise your risk of an eye infection.
How to use Verkazia (cyclosporine):
Review the Instructions for Use to get familiar with how to use the medication.
Pull down your lower eyelid with one hand and hold the vial upside down with the other. Tilt your head back and squeeze 1 drop into your affected eye, close your eye, then press your finger on the corner of your eye closest to your nose for 2 minutes.
Repeat these steps if you need to use Verkazia (cyclosporine) in your other eye.
Verkazia (cyclosporine) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Don't let the tip of the vial touch the eye, eyelid, fingers, or other surfaces. Doing so can contaminate Verkazia (cyclosporine) and cause serious harm to the eye, such as infection and vision loss.
Dosage | Quantity | Price as low as | Price per unit |
---|---|---|---|
0.3ml of 0.1% | 400 vials | $1808.45 | $4.52 |
Each drop of Verkazia (cyclosporine) contains 0.1% of cyclosporine
Adults and children age 4 and older: The typical dose is to place 1 drop in affected eye(s) 4 times a day (morning, noon, afternoon, and evening).
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Anglade, E., et al. (2007). Next-generation calcineurin inhibitors for ophthalmic indications. Expert Opinion on Investigational Drugs.
Kaur, K., et al. (2023). Vernal keratoconjunctivitis. StatPearls.
Leonardi, A., et al. (2023). Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: Pooled analysis of randomised NOVATIVE and VEKTIS trials. Eye.
National Organization for Rare Disorders. (2022). Vernal keratonconjunctivitis.
Santen Incorporated. (2022). Verkazia- cyclosporine emulsion [package insert]. DailyMed.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.